Genscript Biotech (GNNSF) Stock Statistics & Valuation Metrics

Genscript Biotech has a market cap or net worth of $8.76B. The enterprise value is $22.93B.

Market Cap

$8.76B

Enterprise Value

$22.93B

Genscript Biotech has 2,284,025,600 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

2,284,025,600

Owned by Insiders

―

Owned by Institutions

9.69%

Genscript Biotech’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is 5.54%.

Return on Equity (ROE)

-0.13

Return on Assets (ROA)

-0.11

Return on Invested Capital (ROIC)

5.54%

Return on Capital Employed (ROCE)

0.06

Revenue Per Employee

156.40K

Profits Per Employee

-86.85K

Employee Count

6,135

Asset Turnover

0.20

Inventory Turnover

10.26

The current PE Ratio of Genscript Biotech is -12.39. Genscript Biotech’s PEG ratio is 0.00.

PE Ratio

-12.39

PS Ratio

9.86

PB Ratio

2.08

Price to FCF

165.44

Price to Operating Cash Flow

54.05

PEG Ratio

0.00

In the last 12 months, Genscript Biotech had revenue of 959.53M and earned -532.83M in profits. Earnings per share was -0.25.

Revenue

959.53M

Gross Profit

553.20M

Operating Income

255.25M

Pretax Income

-470.53M

Net Income

-532.83M

EBITDA

329.29M

Earnings Per Share (EPS)

-0.25

In the last 12 months, operating cash flow was 149.59M and capital expenditures -99.29M, giving a free cash flow of 50.30M billion.

Operating Cash Flow

149.59M

Free Cash Flow

50.30M

Free Cash Flow per Share

0.02

Genscript Biotech pays an annual dividend of $0.00, resulting in a dividend yield of ―

Dividend Per Share

$0.00

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

0.52%

Earnings Yield

-6.78%

Beta

0.85

52-Week Price Change

114.29%

50-Day Moving Average

4.68

200-Day Moving Average

2.50

Relative Strength Index (RSI)

48.64

Average Volume (3m)

2,246

Genscript Biotech upcoming earnings date is Mar 24, 2027, TBA (Not Confirmed).

Last Earnings Date

Aug 17, 2026

Next Earnings Date

Mar 24, 2027

Ex-Dividend Date

Jun 05, 2017

Genscript Biotech as a current ratio of 1.47, with Debt / Equity ratio of 6.54%

Current Ratio

1.47

Quick Ratio

1.41

Debt to Market Cap

0.16

Net Debt to EBITDA

0.26

Interest Coverage Ratio

14.74

In the past 12 months, Genscript Biotech has paid 61.87M in taxes.

Income Tax

61.87M

Effective Tax Rate

-0.13

Genscript Biotech EV to EBITDA ratio is 47.25, with an EV/FCF ratio of 192.82.

EV to Sales

11.49

EV to EBITDA

47.25

EV to Free Cash Flow

192.82

EV to Operating Cash Flow

64.83

Genscript Biotech has $831.18M in cash and marketable securities with $254.68M in debt, giving a net cash position of $576.50M billion.

Cash & Marketable Securities

$831.18M

Total Debt

$254.68M

Net Cash

$576.50M

Net Cash Per Share

$0.25

Tangible Book Value Per Share

$1.78

Gross margin is 51.99%, with operating margin of 14.88%, and net profit margin of -75.40%.

Gross Margin

51.99%

Operating Margin

14.88%

Pretax Margin

-69.85%

Net Profit Margin

-75.40%

EBITDA Margin

24.32%

EBIT Margin

14.88%

The average price target for Genscript Biotech is $4.76, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$4.76

Price Target Upside

5.77% Upside

Analyst Consensus

Strong Buy

Analyst Count

7

Revenue Growth Forecast

53.11%

EPS Growth Forecast

-119.98%

Smart Score

10

AI Score

―